(Reuters) -Merck & Co said on Friday updated data from its study of its experimental COVID-19 pill showed the drug was significantly less effective in cutting hospitalizations and deaths than previously reported.
A pandemic-spurred demand for flu vaccines in India has surged since a devastating second wave of COVID-19 brought the nation's healthcare system to its knees earlier this year.
(This November 19 story was corrected to say 60% of Americans are fully vaccinated in last paragraph) | Video
Nov 19 More U.S. adults could be eligible for a
booster dose of the COVID-19 vaccine if a panel of experts meets
as planned on Friday and recommends that a third round of the
shots would be beneficial for a broad population.
Pfizer Inc said on Thursday the U.S. government would pay $5.29 billion for 10 million courses of its experimental COVID-19 antiviral drug, as the country rushes to secure promising oral treatments for the disease.
More Americans than ever before died from drug overdoses over a 12-month period, according to federal data released on Wednesday, as the coronavirus pandemic disrupted medical care and increased mental health woes, and as more lethal drugs flooded the streets.
(Reuters) -A European Medicines Agency panel voted against approval of Biogen Inc's Alzheimer's drug Aduhelm, in another blow to prospects for a treatment already grappling with a slow rollout in the United States. | Video
Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's 135-year history.